Who
Jeffrey Scott Riley
Director
Company insider
Files Form 4 as: Director, Gain Therapeutics; Chief Executive Officer, Theriva Biologics.
In numbers
- Trades disclosed
- 20
- Buys
- 5
- Sells
- 0
- Bought
- $129K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 2 Dec 2010
- Last trade
- 15 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 17 Jul 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 24 Jun 2025filed 25 Jun 2025 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 24 Jun 2024filed 26 Jun 2024 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 28 Mar 2024filed 1 Apr 2024 | GANX Gain TherapeuticsBiotechnology | SEC FORM 4 Bought | $116K30,000 at $3.86 | filing |
| 23 Jun 2023filed 26 Jun 2023 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 20 Sep 2022filed 22 Sep 2022 | GANX Gain Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 30 Nov 2016filed 2 Dec 2016 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,129,000 at $0.00 | filing |
| 4 Dec 2015filed 4 Dec 2015 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 8 Jan 2015filed 12 Jan 2015 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —350,000 at $0.00 | filing |
| 17 Apr 2014filed 21 Apr 2014 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 7 Jan 2013filed 7 Jan 2013 | TOVX Theriva BiologicsBiotechnology | SEC FORM 4 Bought | $95 at $1.71 | filing |
| 7 Jan 2013filed 7 Jan 2013 | TOVX Theriva BiologicsBiotechnology | SEC FORM 4 Bought | $4922,895 at $0.17 | filing |
| 3 Jan 2013filed 4 Jan 2013 | TOVX Theriva BiologicsBiotechnology | SEC FORM 4 Bought | $3,4202,000 at $1.71 | filing |
| 3 Jan 2013filed 3 Jan 2013 | TOVX Theriva BiologicsBiotechnology | SEC FORM 4 Bought | $4,9002,800 at $1.75 | filing |
| 2 Jan 2013filed 3 Jan 2013 | TOVX Theriva BiologicsBiotechnology | SEC FORM 4 Bought | $4,8062,700 at $1.78 | filing |
| 3 Feb 2012filed 6 Feb 2012 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 17 Nov 2011filed 21 Nov 2011 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 5 Jan 2011filed 7 Jan 2011 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 2 Dec 2010filed 3 Dec 2010 | TOVX Theriva Biologicsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,333 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.